Finanzen von Vir Biotechnology Inc (VIR)VIRVir Biotechnology Inc

Evaluating the bottom line, Vir Biotechnology, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 30.75%, while the net margin is 33.51%. These profitability ratios, combined with a Return on Equity (ROE) of -26.08%, provide a clear picture of how effectively VIR converts its operational activities into shareholder value.

In the context of the broader market, VIR competes directly with industry leaders such as INBX and SEPN. With a market capitalization of $1.97B, it holds a significant position in the sector. When comparing efficiency, VIR's gross margin of 100.00% stands against INBX's N/A and SEPN's 100.00%. Such benchmarking helps identify whether Vir Biotechnology, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 100% in Q2 2026, indicating excellent profitability on its revenues. However, it also faced a net income loss of $125.7 million in Q1 2026, which highlights ongoing financial challenges.